Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 7, 2020updated 31 Oct 2021 2:22pm

CSL Behring evaluates monoclonal antibody in Covid-19 patients

CSL Behring has started enrolment in a Phase II clinical trial of CSL312 for the treatment of patients with severe respiratory distress caused by Covid-19-related pneumonia.

CSL Behring has started enrolment in a Phase II clinical trial of CSL312 for the treatment of patients with severe respiratory distress caused by Covid-19-related pneumonia.

CSL312 (garadacimab) is a Factor XIIa antagonist monoclonal antibody that is being assessed as a potential treatment for conditions where FXIIa inhibition may improve clinical outcomes.

The multi-centre, double-blind, placebo-controlled Phase II trial will investigate the safety and efficacy of the drug candidate in about 124 adults with Covid-19.

Participants will be administered with CSL312 or placebo, along with standard of care. The primary endpoint of the study is the incidence of tracheal intubation or death.

CSL Behring respiratory therapeutic area R&D Lead Lars Groenke said: “The greatest clinical challenge in treating patients with severe Covid-19 and improving outcomes has been our ability to manage the serious respiratory complications associated with the disease.

“Our hope with CSL312 is to be able to prevent the progression of Covid-19, improve patient outcomes, and provide physicians with an effective tool in the fight against this deadly virus.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Previously, the company collaborated with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland (UQ) to develop, manufacture, and distribute a Covid-19 vaccine candidate.

CSL Behring is also part of the CoVIg-19 Plasma Alliance focused on developing unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine for individuals with serious Covid-19 complications.

In addition, the company is working on a plasma product against Covid-19 for the Australian market to potentially treat patients with serious Covid-19 complications, primarily those progressing towards ventilation.

It also formed an alliance with SAB Biotherapeutics to advance and deliver a new immunotherapy targeting Covid-19. Clinical trials of the medicine are set to launch in North America in the coming months.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU